Oregon Medical Research Center

Advancing care starts with research. Learn how participation in a clinical study for Palmoplantar Pustulosis (PPP) may help shape future treatment options.

We’re currently enrolling a new clinical research study for individuals living with psoriasis. If you or someone you know has moderate-to-severe psoriasis, call us at 503-245-1525!

Happy New Year! 🎉
We’re excited to kick off 2026 by enrolling for new clinical research studies focused on Chronic Hives Urticaria (CSU), Psoriasis, Palmoplantar Pustulosis (PPP), and Hidradenitis Suppurativa (HS). Here’s to a year of progress 🤍
—
¡Feliz Año Nuevo! 🎉
Estamos muy emocionados de comenzar 2026 inscribiendo participantes para nuevos estudios de investigación clínica enfocados en urticaria crónica (CSU), psoriasis, pustulosis palmoplantar (PPP) y hidradenitis supurativa (HS). ¡Por un año lleno de avances! 🤍

We've moved! Oregon Medical Research Center has moved to the South Waterfront in Portland, Oregon.

Our new address is 1750 S Harbor Way, Suite 330, Portland, OR 97201. Our phone number remains the same: 503-245-1525

Dr. Andrew Blauvelt named as one of the world's most influential scientists of 2021.

Each year the consulting and data analysis firm Clarivate compiles an annual list of researchers who have demonstrated significant and broad influence reflected in the publication of multiple papers frequently cited by their peers.

The 2021 list includes about 3,800 researchers in 21 scientific fields, and another 2,800 researchers identified as having exceptional performance across several fields. The citation analysis considered only papers in journals indexed in the Web of Science Core Collection during the period from 2010 to 2020. Highly cited papers are defined as those that rank in the top 1% by citations for field and publication year. The method, papers weighed against others in the same annual cohort, is intended to remove the citation advantage of older papers relative to recently published ones.

Dr. Blauvelt's ranking recognizes his ongoing dedication and expertise in psoriasis research.

Great news for psoriasis patients:
https://www.dermavant.com/dermavant-announces-fda-acceptance-for-filing-of-new-drug-application-nda-for-tapinarof-cream/

With the help of our patients, we are happy to have played a part in the effort to bring this new option to people with psoriasis.

We will also be starting new trials of this drug for people with atopic dermatitis.

Dermavant Announces FDA Acceptance for Filing of New Drug Application (NDA) for Tapinarof Cream for the Treatment of Adults with Plaque Psoriasis – Dermavant – NDA Is Supported by Positive Data From the Phase 3 PSOARING 1 and PSOARING 2 Pivotal Efficacy Trials and Interim Results From the PSOARING 3 Long-Term Safety Study

Exciting times for people with atopic dermatitis/eczema!
https://nationaleczema.org/biologics-eczema-treatment/

Here is a great summary article from the National Eczema Association.

We've been involved with many of the trials of the new treatments discussed. Don't hesitate to reach out to us for more information.

Biologics Are Changing the Landscape of Eczema Treatment | National Eczema Association Over 25 new biologics are in development for treatment of atopic dermatitis, including the monoclonal antibody treatments Tralokinumab, Lebrikizumab, Nemolizumab %

Interested in learning about a new psoriasis treatment (bimekizumab) in late-stage development? Watch Dr. Andrew Blauvelt being interviewed about the recent trial results.

Plaque Psoriasis on the M.D./alert Conversations Conversations in Plaque Psoriasis provides an in-depth look at novel treatments and new studies. Check in frequently for exclusive video interviews, Q&A’s and expert commentary on key issues facing clinicians today.

Psoriasis gets featured in USA's Winter Wellness insert.

See a story on a patient's perspective of psoriasis and about his participation in a clinical study. See page 3.

Winter Wellness Issuu is a digital publishing platform that makes it simple to publish magazines, catalogs, newspapers, books, and more online. Easily share your publications and get them in front of Issuu’s millions of monthly readers. Title: Winter Wellness, Author: Mediaplanet_USA, Name: Winter Wellness, Lengt...

Exciting new psoriasis treatment results coming from a study we are currently conducting at our site.

Bimekizumab shows significant psoriasis skin clearance in phase 3 trial Bimekizumab showed evidence of superior skin clearance in patients with plaque psoriasis compared with adalimumab, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.BE SURE, a phase 3, multicenter, randomized, double-blind, active comparator-controll...

Interesting info. about a new investigational treatment for psoriasis being studied at our site.

Nonliving microbe may be effective, safe oral treatment for psoriasis A drug comprised of a nonliving single strain commensal microbe showed signs of safe and effective treatment of mild to moderate psoriasis, according to a presentation at the European Academy of Dermatology and Venereology virtual congress.“EDP1815 is a nonlive pharmaceutical preparation of a....

New studies now enrolling:
-Mild-to-Moderate Psoriasis
-Moderate-to-Severe Atopic Dermatitis (Eczema)
-Lichen Planus

Visit www.oregonmedicalresearch.com to learn more and SIGN UP today.